India Glycols Reports Strong Q1 FY27 Results Amidst Demerger Progress

Consolidated Revenue: ₹2,988.44 crore
Consolidated PAT: ₹96.83 crore

Reader Takeaway: Strong Q1 financials overshadowed by significant progress in NCLT-sanctioned demerger plan.

What just happened

India Glycols Limited announced its financial results for the first quarter of the fiscal year 2026-27 (Q1 FY27). The company reported consolidated revenue from operations of ₹2,988.44 crore and a consolidated Profit After Tax (PAT) of ₹96.83 crore. On a standalone basis, the revenue stood at ₹2,986.92 crore, with PAT at ₹76.59 crore.

Why this matters

The financial performance provides investors with a clear picture of the company's current operational health. More importantly, the National Company Law Tribunal (NCLT) sanctioned the company's Composite Scheme of Arrangement on July 17, 2026. This sanction is a critical milestone towards the demerger of the Bio Pharma undertaking and the Spirits & Biofuel undertaking into separate entities.

The backstory

Previously, India Glycols had planned to amalgamate Kashipur Holdings Limited (KHL) into the main company. However, this plan was revised to solely focus on the demerger of its distinct business verticals. This strategic realignment aims to unlock value by creating more focused business units.

What changes now

With the NCLT's sanction, India Glycols is poised to move to the next stage of implementation. The company is awaiting the certified true copy of the NCLT order. Once received, it will enable the formal separation of the Bio Pharma business and the Spirits & Biofuel business, allowing each to pursue its independent growth strategies.

Risks to watch

While the demerger is progressing, investors will need to monitor the timely receipt of the certified NCLT order and the subsequent steps for the formal demerger. Any delays could impact the expected value unlocking from the restructuring.

Peer comparison

India Glycols operates in the chemicals and potable spirits sectors. Its financial performance and strategic moves, especially the demerger, will be compared against other players in these diversified industries.

Context metrics (time-bound)

• Q1 FY27 Consolidated Revenue: ₹2,988.44 crore
• Q1 FY27 Consolidated PAT: ₹96.83 crore
• NCLT Demerger Scheme Sanction Date: July 17, 2026

What to track next

Investors should closely follow the company's announcements for the issuance of the certified NCLT order. The subsequent steps in the demerger process, including the listing of the demerged entities, will be key events to monitor.